title: Cellular recognition and HLA restriction of a midsequence HBsAg peptide in hepatitis B vaccinated individuals.
abstract: Vaccination with native HBsAg results in both a humoral and a cellular immune response in humans. In individuals who responded to vaccination, the HBsAg (S region) specific response, as measured by cell proliferation, diminished significantly after 12 weeks, a time when the antibody response was still vigorous. Reduced and nonreduced HBsAg were equivalent in eliciting lymphocyte proliferation. Anti-MHC class II monoclonal antibodies were used in blocking studies to demonstrate that anti-HLA-DR but not anti-HLA-DQ or anti-HLA-DP inhibited specific lymphocyte proliferation to HBsAg. Both the monomer (reduced) and dimer (nonreduced) forms of an immunodominant midsequence HBsAg peptide (amino acid residues 139-146) produced lymphocyte proliferation roughly comparable to that induced by whole HBsAg in 6 of 7 responders immunized with whole HBsAg and the peptide-induced proliferation was blocked by anti-HLA-DR but not by anti-HLA-DP antibodies. These results suggest that HBsAg p 139-146 is a major immunodominant peptide of HBsAg and is restricted by HLA-DR.
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA.
authors.forename: H
authors.initials: H
authors.lastname: Deulofeut
authors.forename: A
authors.initials: A
authors.lastname: Iglesias
authors.forename: N
authors.initials: N
authors.lastname: Mikael
authors.forename: D H
authors.initials: DH
authors.lastname: Bing
authors.forename: Z
authors.initials: Z
authors.lastname: Awdeh
authors.forename: J
authors.initials: J
authors.lastname: Yunis
authors.forename: D
authors.initials: D
authors.lastname: Marcus-Bagley
authors.forename: M S
authors.initials: MS
authors.lastname: Kruskall
authors.forename: C A
authors.initials: CA
authors.lastname: Alper
authors.forename: E J
authors.initials: EJ
authors.lastname: Yunis
mesh_terms: D000595:Amino Acid Sequence; D004306:Dose-Response Relationship, Immunologic; D006684:HLA-DR Antigens / Q000276:immunology*; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control; D006510:Hepatitis B Antibodies / Q000096:biosynthesis*; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006801:Humans; D007111:Immunity, Cellular; D007117:Immunization, Secondary; D008213:Lymphocyte Activation / Q000276:immunology; D008969:Molecular Sequence Data; D010084:Oxidation-Reduction; D010446:Peptide Fragments / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D013997:Time Factors; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000276:immunology
chemical_list: D006684:HLA-DR Antigens; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; C075652:Heptavax B; D010446:Peptide Fragments; D014614:Vaccines, Synthetic